Channel Bioscience News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Channel Bioscience. Real-time updates on events, politics, business and more.

Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences

February 25, 2022

/PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven") announced today that it has entered into a definitive...

United States Michael Bozik Irfan Qureshi Jen Porcelli Steven Dworetzky Knopp Biosciences

Source: prnewswire.com

Biohaven pays $100M for epilepsy drug prospect; strikes deal for BMS muscle med

February 25, 2022

Neuroscience drug developer Biohaven Pharmaceuticals is expanding its pipeline to include epilepsy and spinal muscular atrophy. The drug developer is acquiring Channel Bioscience and licensing global rights to a Phase 3-ready drug from Bristol Myers Squibb.

Michael Bozik Knopp Biosciences Xenon Pharmaceuticals Bausch Health Companies Bristol Myers Squibb Valeant Pharmaceuticals

Source: medcitynews.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Channel Bioscience News Today

Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences

Biohaven pays $100M for epilepsy drug prospect; strikes deal for BMS muscle med

Explore More Categories